Aug 31, 2026, 8:00 AM EDT · 4 weeks ago Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
2026-08-11T14:25:19.000Z · 7 weeks ago Alpha Tau price target raised to $16 from $15 at H.C. Wainwright
Aug 10, 2026, 8:00 AM EDT · 7 weeks ago Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Jul 21, 2026, 8:30 AM EDT · 2 months ago Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
2026-07-15T13:15:30.000Z · 2 months ago Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer
Jul 15, 2026, 8:30 AM EDT · 2 months ago Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
2026-06-23T16:01:28.000Z · 3 months ago Alpha Tau treats first glioblastoma patient in Israel with Alpha DaRT
Jun 23, 2026, 8:30 AM EDT · 3 months ago Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
2026-06-11T13:17:41.000Z · 3 months ago Alpha Tau gets FDA clearance to complete enrollment in REGAIN trial
Jun 11, 2026, 8:30 AM EDT · 3 months ago Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Jun 3, 2026, 8:30 AM EDT · 4 months ago Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
2026-06-01T13:43:39.000Z · 4 months ago Alpha Tau reports positive survival data from pancreatic cancer study
Jun 1, 2026, 9:00 AM EDT · 4 months ago Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
May 18, 2026, 4:01 PM EDT · 4 months ago Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12T10:48:07.000Z · 4 months ago Alpha Tau price target raised to $15 from $12 at H.C. Wainwright
May 11, 2026, 7:00 AM EDT · 4 months ago Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
May 8, 2026, 9:10 AM EDT · 4 months ago Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
May 8, 2026, 9:00 AM EDT · 4 months ago Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
May 7, 2026, 9:00 AM EDT · 4 months ago Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas Institute
May 5, 2026, 9:14 AM EDT · 5 months ago Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
May 4, 2026, 9:17 AM EDT · 5 months ago Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Apr 29, 2026, 9:00 AM EDT · 5 months ago Medical University of South Carolina and Revival Healthcare Capital Announce Five-Year Strategic Innovation Partnership
Apr 27, 2026, 9:01 AM EDT · 5 months ago Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies
Apr 23, 2026, 9:02 AM EDT · 5 months ago Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)
Apr 23, 2026, 9:01 AM EDT · 5 months ago Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial
Mar 31, 2026, 9:15 AM EDT · 6 months ago Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026
Mar 16, 2026, 10:02 AM EDT · 6 months ago Alpha Tau to Present at Sidoti March Virtual Small Cap Conference
Mar 9, 2026, 4:02 PM EDT · 6 months ago Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update
Feb 24, 2026, 8:51 PM EST · 7 months ago HekaBio and Alpha Tau Medical Obtain Approval in Japan for Solid Tumor Treatment Alpha DaRT
Feb 24, 2026, 9:00 AM EST · 7 months ago Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Feb 3, 2026, 12:37 PM EST · 8 months ago Altamirano PLLC Issues Investor Notice on Inspired Healthcare Capital (IHC) Chapter 11 Bankruptcy Filing
Jan 29, 2026, 9:00 AM EST · 8 months ago Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Jan 6, 2026, 9:00 AM EST · 9 months ago Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
Jan 5, 2026, 9:00 AM EST · 9 months ago Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Dec 9, 2025, 9:00 AM EST · 9 months ago Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
Nov 20, 2025, 4:05 PM EST · 10 months ago Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 11, 2025, 8:30 AM EST · 10 months ago Alpha Tau to Participate at Jefferies Global Healthcare Conference in London
Oct 21, 2025, 8:30 AM EDT · 11 months ago Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness
Oct 17, 2025, 10:04 AM EDT · 11 months ago Altamirano PLLC Issues Notice to Inspired Healthcare Capital (IHC) Investors on Recovery Options
Sep 2, 2025, 8:30 AM EDT · 1 year ago Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
Aug 27, 2025, 8:30 AM EDT · 1 year ago Alpha Tau to Participate in Five September Investor Conferences
Aug 11, 2025, 4:02 PM EDT · 1 year ago Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 25, 2025, 9:04 AM EDT · 1 year ago Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical
May 19, 2025, 4:01 PM EDT · 1 year ago Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025, 4:01 PM EDT · 1 year ago Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
Apr 28, 2025, 9:00 AM EDT · 1 year ago Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical ORMP
Apr 28, 2025, 9:00 AM EDT · 1 year ago Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals ORMP
Apr 2, 2025, 8:30 AM EDT · 1 year ago Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma
Mar 12, 2025, 4:02 PM EDT · 1 year ago Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update
Feb 24, 2025, 8:30 AM EST · 1 year ago Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification
Jan 27, 2025, 9:00 AM EST · 1 year ago Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
Dec 18, 2024, 8:30 AM EST · 1 year ago Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day
Dec 17, 2024, 9:00 AM EST · 1 year ago Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
Dec 11, 2024, 8:30 AM EST · 1 year ago Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference
